HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo

British Journal of Cancer

Volumn 92, Issue 8, 2005, Pages 1430-1441

  Pukae, L ^a   Kanakaraj, P ^a   Humphreys, R ^a   Alderson, R ^a   Bloom, M ^a   Sung, C ^a   Riccobene, T ^a   Johnson, R ^a   Fiscella, M ^a   Mahoney, A ^a   Carrell, J ^a   Boyd, E ^a   Yao, X T ^a   Zhang, L ^a   Zhong, L ^a   Von Kerczek, A ^a   Shepard, L ^a   Vaughan, T ^b   Edwards, B ^b   Dobson, C ^b   Salcedo, T ^a   Albert, V ^a   more..

^a GLAXOSMITHKLINE   (United States)

^b MEDIMMUNE LTD   (United Kingdom)

Author keywords

Antibody; Apoptosis; Chemotherapeutic agents; TRAIL; TRAIL receptor 1

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CARBOPLATIN; CASPASE 3; CASPASE 8; CASPASE 9; CISPLATIN; DEATH RECEPTOR 4; DEATH RECEPTOR 5; FLUOROURACIL; IRINOTECAN; MAPATUMUMAB; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HGS ETRI; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BID; TOPOTECAN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; COLON TUMOR; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG SENSITIVITY; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KIDNEY TUMOR; LUNG NON SMALL CELL CANCER; MALE; MOUSE; NONHUMAN; OSMOTIC MINIPUMP; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR; TUMOR CELL; TUMOR CELL LINE; TUMOR REGRESSION; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HALF-LIFE; HUMANS; MALE; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 21044441651     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602487     Document Type: Article

References (53)

1. Arizono Y, Yoshikawa H, Naganuma H, Hamada Y, Nakajima Y, Tasaka K (2003) A mechanism of resistance to TRAIL/Apo2L-induced apoptosis of newly established glioma cell line and sensitisation to TRAIL by genotoxic agents. Br J Cancer 88: 298-306
2. Ashkenazi A, Pai R, Fong S, Leung S, Lawrence D, Marsters S, Blackie C, Chang L, McMurtrey A, Herbert A, DeForge L, Koumenis I, Lewis D, Harris L, Bussiere J, Koeppen H, Shahrokn Z, Schwall R (1999) Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104: 155-162
3. Asakuma J, Sumitomo M, Asano T, Hayakawa M (2003) Selective Akt inactivation and tumor necrosis actor-related apoptosis-inducing ligand sensitization of renal cancer cells by low concentrations of paclitaxel. Cancer Res 63: 1365-1370
4. Berger M, Shankar V, Vafai A (2002) Therapeutic applications of monoclonal antibodies. Am J Med Sci 324: 14-30
5. Bouralexis S, Evdokiou A, Hay S, Atkins G, Findlay D (2001) Enhanced apoptosis of soft tissue sarcoma cells with chemotherapy: a potential new approach using TRAIL. J Orthop Surg 9: 19-22
6. Bouralexis S, Findlay D, Atkins G, Laabrinidis A, Hay S, Evdokiou A (2003) Progressive resistance of BTK-143 osteosarcoma cells to Apo2L/TRAIL-induced apoptosis is mediated by acquisition of DcR2/TRAIL-R4 expression: resensitisation with chemotherapy. Br J Cancer 89: 206-214
7. Buchsbaum D, Zhou T, Grizzle W, Oliver P, Hammond C, Zhang S, Carpenter M, LoBuglio A (2003) Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model. Clin Cancer Res 9: 3731-3741
8. Burns T, El-Deiry W (2001) Identification of inhibitors of TRAIL-induced death (ITIDs) in the TRAIL-sensitive colon carcinoma cell line SW480 using a genetic approach. J Biol Chem 276: 37879-37886
9. Chawla-Sarkar M, Leaman D, Jacobs B, Borden E (2002) IFN-beta pretreatment sensitizes human melenoma cells to TRAIL/Apo2 ligand-induced apoptosis. J Immunol 169: 847-855
10. Chuntharapai A, Dodge K, Grimmer K, Schroeder K, Masters SA, Koeppen H, Ashkenazi A, Kim KJ (2001) Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4. J Immunol 166: 4891-4898
11. Evdokiou A, Bouralexis S, Atkins G (2002) Chemotherapeutic agents sensitize osteogenic sarcoma cells, but not normal human bone cells, to apo2L/Trail-induced apoptosis. Int J Cancer 99: 491-504
12. Gliniak B, Le T (1999) Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11. Cancer Res 59: 6153-6158
13. Griffith T, Rauch C, Smolak P, Waugh J, Boiani N, Lynch D, Smith C, Goodwin R, Kubin M (1999) Functional analysis of TRAIL receptors using monoclonal antibodies. J Immunol 162: 2597-2605
14. Ichikawa K, Liu W, Zhao L, Wang Z, Liu D, Ohtsuka T, Zhang H, Mountz J, Koopman W, Kimberly R, Zhou T (2001) Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med 7: 954-960
15. Jackson R, McCafferty J, Joshson K, Pope A, Roberts A, Chiswell D, Clackson T, Griffiths A, Hoogenboom H, Winter G (1992) Selection of variants of antibodies and other protein molecules using display on the surface of bacteriophage. In Protein Engineering: A Practical Approach Rees AR, Sternberg M, Wetzel R (eds) pp 277-301. Oxford: IRL Press
16. Jang Y, Park K, Chung H, Kim H (2003) Analysis of the phenotypes of Jurkat clones with different TRAIL-sensitivities. Can Lett 194: 107-117
17. Kaliberov S, Stackhouse M, Kaliberova L, Zhou T, Buchsbaum D (2004) Enhanced apoptosis following treatment with TRA-8 anti-human DR5 monoclonal antibody and overexpression of exogenous Bax in human glioma cells. Gene Ther 11: 658-667
18. Kashmiri S, Shu L, Padlam E, Milenic D, Schlom J, Hand P (1995) Generation, characterization, and in vivo studies of humanized anti-carcinoma antibody CC49. Hybridoma 14: 461 -473
19. Keane M, Ettenberg S, Nau M, Russell E, Lipkowitz S (1999) Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res 59: 734-741
20. Kelley R, Totpal K, Lindstrom S, Mathieu M, Billed K, Deforge L, Pai R, Hymowitz S, Ashkenazi A (2005) Receptor-selective mutants of Apo2L/TRAIL reveal a greater contribution of DR5 than DR4 to apoptosis signaling. J Biol Chem 280: 2205-2212
21. Kelley S, Harris L, Xie D, Deforge L, Totpal K, Bussiere J, Fox J (2001) Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther 299: 31-38
22. Kim K, Fisher M, Xu S, El-Deiry W (2000) Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clin Cancer Res 6: 335-346
23. Kothny-Wilkes G, Kulms D, Poppelmann B, Luger T, Kubin M, Schwartz T (1998) Interluekin-1 protects transformed keratinocytes from tumor necrosis factor-related apoptosis-inducing ligand. J Biol Chem 273: 29247-29253
24. Lawrence D, Shahrokh Z, Marsters S, Achilles K, Shih D, Mounho B, Hillan K, Totpal K, DeForge L, Schow P, Hooley J, Sherwood S, Pai R, Leung S, Khan L, Gliniak B, Bussiere J, Smith C, Strom S, Kelley S, Fox J, Thomas D, Ashkenazi A (2001) Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 7: 383385
25. LeBlanc H, Ashkenazi A (2003) Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ 10: 66-75
26. LeBlanc H, Lawrence D, Varfolomeev E, Totpal K, Morlan J, Schow P, Fong S, Schwall R, Sinicropi D, Ashkenazi A (2002) Tumor-cell resistance to death receptor-induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat Med 8: 274-281
27. Levine R (1990) In Pharmacology: Drug Actions and Reactions Levine R (ed) pp 110. Boston: Litttle Brown & Co
28. Lin Y, Nguyen C, Mendoza J, Escandon E, Fei D, Meng Y, Modi N (1999) Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J Pharmacol Exp Ther 288: 371-378
29. MacFarlane M (2003) TRAIL-induced signaling and apoptosis. Toxicol Lett 139: 89-97
30. Marks J, Hoogenboom H, Bonnert T, McCafferty J, Griffiths A, Winter G (1991) By-passing immunization: human antibodies from V-gene libraries displayed on phage. J Mol Biol 222: 581-597
31. Muhlenbeck F, Schneider P, Bodmer J, Schwenzer R, Hauser A, Schubert G, Scheurich P, Moosmayer D, Tschopp J, Wajant H (2000) The tumor necrosis factor-related apoptosis-inducing ligand receptors TRAIL-R1 and TRAIL-R2 have distinct cross-linking requirements for initiation of apoptosis and are non-redundant in JNK activation. J Biol Chem 275: 32208-32213
32. Nagane M, Pan G, Weddle J, Dixit V, Cavenee W, Huang H (2000) Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer Res 60: 847-853
33. Naka T, Sugamura K, Hylander B, Widmer M, Rustum Y, Repasky E (2002) Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice. Cancer Res 62: 5800-5806
34. Nimmanapalli R, Perkins C, Orlando M, O'Bryan E, Nguyen D, Bhalla K (2001) Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels. Cancer Res 61: 759-763
35. Ohtsuka T, Buchsbaum D, Oliver P, Makhija D, Kimberly R, Zhou T (2003) Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway. Oncogene 22: 2034-2044
36. Ozoren N, El-Deiry W (2003) Cell surface death receptor signaling in normal and cancer cells. Semin Cancer Biol 13: 135-147
37. Park J, Lee J, Rang M, Park K, Jeon Y, Lee H, Kwon H, Park H, Yeo K, Lee K (1995) Characterization of cell lines established from human hepatocellular carcinoma. Int J Cancer 62: 276-282
38. Pitti R, Marsters S, Ruppert S, Donahue C, Moore A, Ashkenazi A (1996) Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 271: 12687-12690
39. Ray S, Almasan A (2003) Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11. Cancer Res 63: 4713-4723
40. Sayers TJ, Brooks A, Koh CY, Ma W, Seki N, Raziuddin A, Blazar BR, Zhang X, Elliott PJ, Murphy WJ (2003) The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP. Blood 102: 303-310
41. Shimoyama S, Mochizuki Y, Kusada O, Kaminishi M (2002) Supra-additive antitumor activity of 5FU with tumor necrosis factor-related apoptosis-inducing ligand on gastric and colon cancers in vitro. Int J Oncol 21: 643-648
42. Singh T, Shankar S, Chen X, Asim M, Srivastava R (2003) Synergistic interaction of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo. Cancer Res 63: 5390-5400
43. Song J, Song D, Herlyn M, Petruk K, Hao C (2003) Cisplatin down-regulation of cellular Fas-associated death domain-like interleukin-1beta-converting enzyme-like inhibitory proteins to restore tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human melanoma cells. Clin Can Res 9: 4255-4266
44. Sprick M, Weigand M, Rieser E, Rauch C, Juo P, Blenis J, Krammer P, Walczak H (2000) FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 12: 599-609
45. Srivastava R (2001) TRAIL/Apo-2L: mechanisms and clinical applications in cancer. Neoplasia 3: 535-546
46. Trauzold A, Schmiedel S, Roder C, Tams C, Christgen M, Arlt SO, Westphal S, Kapischke M, Ungefroren H, Kalthoff H (2003) Multiple and synergistic deregulations of apoptosis-controlling genes in pancreatic carcinoma cells. Br J Cancer 89: 1714-1721
47. Vaughan T, Williams A, Pritchard K, Osbourn J, Pope A, Earnshaw J, McCafferty J, Hodits R, Wilton J, Johnson K (1996) Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nat Biotechnol 14: 309-314
48. Viera P, Rajewsky K (1988) The half-lives of serum immunoglobulins in mice. Eur J Immunol 18: 313-316
49. Walczak H, Miller R, Ariail K, Gliniak B, Griffith T, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin R, Rauch C, Schuh J, Lynch D (1999) Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5: 157-163
50. Wiley S, Schooley K, Smolak P, Din W, Huang C, Nicholl J, Sutherland G, Smith T, Rauch C, Smith C, Goodwin R (1995) Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 6: 673-682
51. Yagita H, Takeda K, Hayakawa Y, Smyth M, Okumura K (2004) TRAIL and its receptors as targets for cancer therapy. Cancer Sci 95: 777-783
52. Yamanaka T, Shiraki K, Sugimoto K, Ito T, Fujikawa K, Ito M, Takase K, Moriyama M, Nakano T, Suzuki A (2000) Chemotherapeutic agents augment TRAIL-induced apoptosis in human hepatocellular carcinoma cell lines. Hepatology 32: 482-490
53. Zhang X, Zhang X, Gray C, Nguyen T, Hersey P (2001) Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of human melanoma is regulated by Smac/DIABLO release from mitochondria. Cancer Res 61: 7339-7348